# Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannová,G. Bodoky,Rocio García‐Carbonero,Tudor–Eliade Ciuleanu,David C. Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García‐Alfonso,Kentaro Yamazaki,Philip R. Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao-Chun Chang,Federico Nasroulah |
| Citations | 961 |
| DOI | 10.1016/s1470-2045(15)70127-0 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2121847974 |
| PMID | 25877855 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Sara Lonardi](https://scholariq.org/researchers/sara-lonardi/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Paper topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.